Sweden's Mendus Q2 net loss narrows
Sweden's Mendus Q2 net loss narrows
Overview
Sweden biopharma firm's Q2 net loss narrowed yr/yr
Company reported no revenue for Q2 2026
Clinical trials for lead product vididencel advanced in AML and CML during the quarter
Outlook
Mendus expects further clinical catalysts for vididencel in myeloid blood cancers in 2026
Company expects initial VITAL-CML trial readout in second half of 2026
VITAL-TFR2 trial in CML anticipated to start in second half of 2026
Result Drivers
CLINICAL TRIAL PROGRESS - Co cited advancement of vididencel trials in AML and CML, including reaching enrollment milestones and regulatory approvals
COLLABORATIONS - Co entered collaboration with South Australian Health and Medical Research Institute to prepare for new CML trial
ADVISORY BOARD - Co established Clinical Advisory Board of international experts to support clinical development
Company press release: ID:nMFN4tGlDN
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Adjusted Loss Per Share |
| SEK 0.34 |
|
Q2 Net Loss |
| SEK 21.38 mln |
|
Q2 Operating Profit |
| -SEK 20.50 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Mendus AB (publ) is SEK33.00, about 391.8% above its August 19 closing price of SEK6.71
Reuters Recommended Reads
Aug 20 - Sweden's Ascelia Pharma Q2 operating loss narrows
Aug 20 - Sweden's SynAct Pharma Q2 net loss narrows on lower expenses
Aug 19 - Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)